SCHEMBL3704156

SCHEMBL3704156

CCCCNC(=O)CCC/C=C\CCCCCCCCCC(=O)O

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 8/20 0.88
KDM4E B2RXH2 1/20 0.81
MAPT P10636 2/20 0.78
MEN1 O00255 1/20 0.78
KMT2A Q03164 1/20 0.78
SLC6A5 Q9Y345 1/20 0.78
CNR1 P21554 3/20 0.72
FAAH O00519 2/20 0.71
CNR2 P34972 2/20 0.71
TERT O14746 2/20 0.67
GMNN O75496 1/20 0.67
USP2 O75604 1/20 0.67
LMNA P02545 1/20 0.67
CYP1A2 P05177 1/20 0.67
POLB P06746 1/20 0.67
CYP2C9 P11712 1/20 0.67
ALOX15 P16050 1/20 0.67
APEX1 P27695 1/20 0.67
CYP2C19 P33261 1/20 0.67
RECQL P46063 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9947771 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL15297199 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
Sebacic Acid SCHEMBL30382131 0.94 EPHX2 (1.00) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL15296972 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL15297170 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL15296899 0.94 MAPT (0.89) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL21983254 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL9947772 0.94 EPHX2 (0.94) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL10081341 0.92 EPHX2 (0.91) EPHX2KDM4EMAPTMEN1KMT2A
SCHEMBL15220082 0.92 EPHX2 (0.79) EPHX2KDM4EMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365183-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2022-06-21 US disclosed
US-11365183-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2022-06-21 US disclosed
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-10-17 US disclosed
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-10-17 US disclosed
US-10287262-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-05-14 US disclosed
US-10287262-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2019-05-14 US disclosed
EP-3222612-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2017-09-27 EP disclosed
EP-2376432-B1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) 2017-04-12 EP disclosed
EP-2376432-B1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) 2017-04-12 EP disclosed
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2016-11-10 US disclosed
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) 2016-11-10 US disclosed
US-9272991-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2016-03-01 US disclosed
US-9272991-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2016-03-01 US disclosed
US-9272991-B2 Eicosanoid derivatives MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2016-03-01 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) 2012-05-17 US disclosed
WO-2010081683-A1 NOVEL EICOSANOID DERIVATIVES Max-Delbrück-Centrum für Molekulare Medizin (DE) 2010-07-22 WO disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 EP disclosed
EP-2208720-A1 Novel eicosanoid derivatives Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) 2010-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122972-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 EPHX2 486/4885KDM4E 4277/4885MAPT 4873/4885
US-10287262-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 EPHX2 500/4885KDM4E 4434/4885MAPT 4861/4885
US-11365183-B2 Eicosanoid derivatives FABP3, PTGER3, PTGES3 EPHX2 500/4885KDM4E 4434/4885MAPT 4861/4885
US-20160326128-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 EPHX2 559/4885KDM4E 4445/4885MAPT 4864/4885
US-20190315701-A1 NOVEL EICOSANOID DERIVATIVES FABP3, PTGER3, PTGES3 EPHX2 559/4885KDM4E 4445/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.